ClinicalTrials.gov record
Completed Phase 2 Interventional

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

ClinicalTrials.gov ID: NCT04432454

Public ClinicalTrials.gov record NCT04432454. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )

Study identification

NCT ID
NCT04432454
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sermonix Pharmaceuticals Inc.
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

  • Lasofoxifene and abemaciclib (VERZENIO (R)). Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 28, 2020
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Last update posted
Feb 12, 2025

2020 – 2025

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
University of Alabama at Birmingham (UAB) - Comprehensive Cancer Center Birmingham Alabama 35294-3300
Yuma Regional Medical Center Yuma Arizona 85364
Compassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley Fountain Valley California 92708
St. Joseph Health Santa Rosa California 95403
Mayo Jacksonville Jacksonville Florida 32224
Illinois Cancer Care Peoria Illinois 61704
Beacon Health System Memorial Regional Cancer Center South Bend Indiana 46601
Mayo Clinic Rochester Rochester Minnesota 55905
New Jersey Cancer Care, PA Belleville New Jersey 07109
Cleveland Clinic Cleveland Ohio 44195
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Mary Crowley Cancer Research Dallas Texas 75230
MD Anderson Cancer Center Houston Texas 77030-4009
Oncology Consultants, P.A. Houston Texas 77030
Hematology Oncology Associates of Fredericksburg Fredericksburg Virginia 22408
Northwest Medical Specialists, PLLC (NWMS) Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04432454, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04432454 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →